BioCentury
ARTICLE | Finance

Fungal flexibility

How antifungal play Amplyx plans to deploy series C

August 4, 2017 11:54 PM UTC

Undisclosed first-in-human safety data persuaded a host of new investors to infuse Amplyx Pharmaceuticals Inc. with enough cash to pursue multiple indications for its broad-spectrum antifungal, APX001.

On Aug. 2, the biotech raised $67 million in an oversubscribed series C round that was led by Sofinnova Ventures, with participation from new investors Arix Bioscience, Lundbeckfonden Ventures and Pappas Capital...

BCIQ Company Profiles

Amplyx Pharmaceuticals Inc.